Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.23

+4.7%
HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

At a Glance

Live Snapshot
Market Cap$155.38M
EPS-1.6700
P/E Ratio-34.52
Earnings Date08/13/2026

uncy

Other Current Assets

Last Annual Value

7.69M

3-Year CAGR

264%

5-Year CAGR

107%

10-Year CAGR

%

Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Competitors Analysis of Other Current Assets

UNCY · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
7.69M
187.1%127.6%N/A 
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
0.00
N/AN/AN/A
CBUS logo
Cibus, Inc.
NASDAQ:CBUS
1.44M
-10.2%23.7%N/A
5.05M
-21.6%N/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-546.00
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
63.21M
280.2%151.4%N/A
4.41M
-29.5%N/AN/A
2.28M
-19.3%22.7%N/A
0.00
N/AN/AN/A
1.86M
-5.9%N/AN/A
2.24M
-1.1%N/AN/A
Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc. Fair Value Envelope

UNCY · NASDAQ

Our analysis suggests that UNCY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.23, this represents a potential HIDDEN relative to our calculated worth for Unicycive Therapeutics, Inc..

Intrinsic Value
Current Price: $7.23